The estimated Net Worth of Resonance Llc General is at least $94.4 Milion dollars as of 30 April 2024. Resonance General owns over 26,000 units of Clene Nanomedicine stock worth over $93,260,506 and over the last 3 years Resonance sold CLNN stock worth over $1,122,738.
Resonance has made over 6 trades of the Clene Nanomedicine stock since 2022, according to the Form 4 filled with the SEC. Most recently Resonance sold 26,000 units of CLNN stock worth $10,660 on 30 April 2024.
The largest trade Resonance's ever made was selling 181,818 units of Clene Nanomedicine stock on 16 May 2022 worth over $400,000. On average, Resonance trades about 79,094 units every 136 days since 2022. As of 30 April 2024 Resonance still owns at least 15,313,712 units of Clene Nanomedicine stock.
You can see the complete history of Resonance General stock trades at the bottom of the page.
Resonance's mailing address filed with the SEC is 6510 SOUTH MILLROCK DRIVE, SUITE 250, , HOLLADAY,, UT, 84121.
Over the last 4 years, insiders at Clene Nanomedicine have traded over $1,293,164 worth of Clene Nanomedicine stock and bought 19,236,803 units worth $21,152,263 . The most active insiders traders include David J Matlin, Chidozie Ugwumba a Alison Mosca. On average, Clene Nanomedicine executives and independent directors trade stock every 26 days with the average trade being worth of $2,786,272. The most recent stock trade was executed by Robert Dee Etherington on 29 July 2024, trading 27,320 units of CLNN stock currently worth $81,960.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.
Clene Nanomedicine executives and other stock owners filed with the SEC include: